๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
13.4K subscribers
1.33K photos
11 videos
555 files
687 links
ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู…

ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ

ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ:
ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ
ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„
ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ
ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ

ู„ู„ุชูˆุงุตู„:
Insta: hussian_8x

@AronX2bot
Download Telegram
Forwarded from AroNchat
https://docs.google.com/forms/d/e/1FAIpQLSeV5Ee9LB-3h0xZcBA7hqOll-OlhqGlRzwDcwH5weT2mysiqA/viewform?usp=header
ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ุง ู…ุฌู…ูˆุนุฉ ู…ู† ุทู„ุงุจ ู…ุฑุญู„ุฉ ุฎุงู…ุณู‡ ู…ู…ูƒู† ุชุณุงุนุฏูˆู†ู‡ ูˆุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ุจุฎุตูˆุต ุงู„ุฌุฑุนู‡ ุงู„ุณุงู…ู‡ ู„ู„ุจุฑุงุณูŠุชุงู…ูˆู„ (ูู‚ุท ุทู„ุงุจ ุงู„ุฎุงู…ุณ ูˆุงู„ุฎุฑูŠุฌูŠู†)
โค2
Forwarded from AroNchat
โค1
ุตูˆุฑ ู…ุณุชุฎุฏู…ุฉ ููŠ ุงู„ุดุฑุญ
โค7
Treatment of ALL

5 elements:
Induction
CNS directed Treatment
Consolidation
Reinduction
Maintenance phase


1. Induction Therapy:
vincristine
L- asparaginase
steroid (prednisone or dexamethasone)
ุงู„ Dexamethazone ู‡ูˆ ุงู„ู…ูุถู„ ู„ุงู† ูŠูƒุฏุฑ ูŠูˆุตู„ ู„ู„ CNS
ู…ู…ฺฉู† ุจุงู„ู€ higher risk patient ู†ุถูŠู ุฏูˆุงุก ู…ู† ู…ุฌู…ูˆุนุฉ anthracycline


2. CNS prophylaxis:

A. Intrathecal:
Cytarabine
MTX
Steroid

B. Systemic chemotherapy: Dexamethasone
high-dose methotrexate

ุจุงู„ุงุถุงูุฉ ุงู„ู‰ ุงู„ุฃุดุนุงุน
craniospinal irradiation (XRT) in selected high-risk patients (T-cell ALL)


3. Consolidation
High dose of chemotherapy

4. Reinduction
A. Interim maintenance 2 months
B. Delayed intensification for 3 months after remission
ู†ูุณ ุงุฏูˆูŠุฉ ุงู„ induction ู†ุนูŠุฏู‡ุง ู…ู† ุฌุฏูŠุฏ

5. Maintenance phase
oral methotrexate
6- mercaptopurine.
2-3 years with low dose


#Leukemia

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค7
Relapse ALL

Chemotherapy
Allogeneic hematopoietic stem cell transplant (allo-HSCT)

Chemotherapy:

๐Ÿ”ธClofarabine โž” active in refractory acute leukemias

๐Ÿ”นBlinatumomab โž” targets CD19, for Ph negative relapsed or refractory ALL

๐Ÿ”ธInotuzumab ozogamicin โž” anti CD-22, used in relapsed and refractory B-ALL

๐Ÿ”นTisagenlecleucel โž” anti-CD19, used in patients with relapsed and refractory B-cell ALL


#Leukemia

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค2
Leukemia โž” Therapy โž” Remission โž” Relapse ๐Ÿ”„
โค7
ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุทู„ุงุจ

ู…ู…ูƒู† ุชุณุงุนุฏูˆู†ุง ุชู…ู„ูˆู† ู‡ุฐุง ุงู„ุจุญุซ ุจู„ุง ุฒุญู…ุฉ ุนู„ูŠูƒู…ุŒ ู…ุง ูŠุทูˆู„ ุจุงู„ุฒุงูŠุฏ ุฏู‚ูŠู‚ุฉ ูˆู†ุต ูƒู„ุด ุณุฑูŠุน ูˆุงุฌูˆุจุชูƒู… ูƒู„ู‡ุง ุชููŠุฏู†ุง ูŠุงุฑูŠุช ุชุฌุงูˆุจูˆู†
โœจ

https://forms.gle/WmmNou4Kv1t1VpKy8
โค7
Treatment of AML

1. Induction
combination of cytarabine and daunorubicin

ู…ู…ูƒู† ู†ุถูŠู ุงู„ู€ gemtuzumab ozogamicin ู„ู„ู€ induction therapy ู„ู„ู…ุฑุถู‰ ูƒุจุงุฑ ุงู„ุณู†

2. Consolidation
use of 2-4 cycles of high-dose cytarabine


๐Ÿซ† Most effective treatment for AML is Allo HSCT


ููŠ ุญุงู„ุฉ ุงู„ู€ CNS Therapy ู†ุณุชุฎุฏู…:
โ— Intrathecal Cytarabine with or without MTX
โ— Systemic High dose Cytarabine



๐Ÿซ†Relapse AML

๐Ÿ”ธHigh dose of Cytarabine
May be combined with: MECCF
Mitoxantrone, Etoposide 2-Chlorodeoxyadenosine, Clofarabine, Fludarabine
๏ปฟ

๐Ÿ”นPatients unable to tolerate intensive chemotherapy ๐Ÿ‘†, use low dose of Cytarabine and Azacitidine



๐Ÿ”ธAlternative therapy:
Ventoclax combined with Decitabine or Azacitidine



#Leukemia

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค5
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
PHARMACOLOGY III 2nd course 4th Stage โ—ใƒปโ—‹ใƒปโ—ใƒปโ—‹ใƒปโ— ุญุณุจ ุงู„ู…ุญุงุถุฑุงุช ุงู„ู…ูˆุญุฏุฉ ูˆ ุงู„ู…ุนุชู…ุฏุฉ ููŠ ุงู„ุงู…ุชุญุงู† ุงู„ุชู‚ูˆูŠู…ูŠ 1. Anti inflammatory 2. Anti inflammatory Explainโ–ท Exam โš• 3. DMARD and GOUT Explainโ–ท Exam โš• 4. Drugs affecting bone metabolism Explainโ–ท Examโ€ฆ
ุทู„ุงุจ ุงู„ุฑุงุจุนุฉ๐Ÿ˜

ู…ูˆ ุงูˆู„ ุฑุณุงู„ุฉ ู…ุซุจุชุฉ(ุนู„ุงุฌูŠุงุช)
ู…ุจุงุดุฑุฉู‹ ุงู„ุซุงู†ูŠุฉ(ูุงุฑู…ุง)

ูˆุงู„ู„ู‡ู ูˆุชุงู„ู„ู‡ู ูˆุจูƒุณุฑ ุงู„ู‡ุงุก ุดุงุฑุญ ูุงุฑู…ุง ูƒูˆุฑุณ ุซุงู†ูŠ ุงู„ุนุงู… ูˆู†ูุณ ุงู„ู…ู†ู‡ุฌ ู‡ู… ู„ุจู†ูƒูˆุช ูˆู…ุงูƒูˆ ูุฑู‚ ูˆุงุฐุง ุงูƒูˆ ูุฑู‚ ู‡ูˆ ุญุฐู ุณุทุฑ ุณุทุฑูŠู†

ูˆุงูŠ ุดูŠ ุชุญุชุงุฌูˆู†ู‡ ุฑุงุณู„ูˆู†ูŠโ™ฅ๏ธ
โค37
๐Ÿ™4โค3
ุทู„ุงุจ ุงู„ุฑุงุจุนุฉ ูˆุงู„ุฎุงู…ุณุฉ

ุงูŠ ูˆุณู… #
ุจุงู„ุฑุณุงู„ุฉ ุงู„ู…ุซุจุชุฉ ู…ู† ุชุถุบุทูˆู† ุนู„ูŠู‡ ุฑุญ ุชุธู‡ุฑ ุนุฏูƒู… ูฃ ุงูŠู‚ูˆู†ุงุช
ู…ู†ุดูˆุฑุงุช ุนุงู…ุฉ
ู…ุญุงุฏุซุงุชูŠ
ู‡ุฐู‡ ุงู„ู…ุญุงุฏุซุฉ
ุชุฎุชุงุฑูˆู† ู‡ุฐู‡ ุงู„ู…ุญุงุฏุซุฉ ุญุชู‰ ุชุญุตู„ูˆู† ูƒู„ ุงู„ุดุบู„ุงุช ุงู„ูŠ ู…ู†ุฒู„ู‡ุง
โค8๐Ÿ‘1
Treatment of CML

๐Ÿ”นfirst- line therapy for newly
diagnosed CP-CML is Tyrosine Kinase Inhibitors TKI

1st G: imatinib

2nd G: dasatinib, nilotinib, and bosutinib

3rd G: Ponatinib

ุงู„ุงุฎูŠุฑ ุงุณุชุฎุฏู…ู‡ ููŠ ุญุงู„ุฉ
CML with T315I mutation

ุขุซุงุฑู‡ุง ุงู„ุฌุงู†ุจูŠุฉ
Myelosuppression, gastrointestinal disturbances, and myalgias

Pleural effusion โž”
ุฎุตูˆุตุง ุงู„ imatinib ูˆ Dasatinib


๐Ÿ”ธHydroxyurea
ู‡ุฐุง ู†ุณุชุฎุฏู…ู‡ ุญุชู‰ ู†ู‚ู„ู„ ุงุนุฏุงุฏ neutrophil ุงูˆ WBC ุญุชู‰ ู†ู…ู†ุน ุญุตูˆู„
Respiratory and neurologic compilations
ู…ุง ุนู†ุฏู‡ ุงูŠ ุชุฃุซูŠุฑ ุนู„ู‰ CML



โญ• Pt suffered from CML, and taken TKI,
ูˆู…ุง ู…ุณุชูุงุฏ ู…ู†ู‡ุง ูŠุนู†ูŠ ุตุงูŠุฑุฉ ุนู†ุฏู‡ resistant ู„ู„ TKI

ู ุงู„ Curative therapy ุจู‡ุงูŠ ุงู„ุญุงู„ุฉ ู‡ูˆ Allo HSCT ุงู„ุนู„ุงุฌ ุงู„ูˆุญูŠุฏ ุงู„ูŠ ูŠุณุจ cure ุจุญุงู„ุฉ CML


๐Ÿ”นOmacetaxine :
indicated for patients in CP- or AP- CML who are resistant or intolerant to two or more TKIs

ูƒุฐู„ูƒ ููŠ ุญุงู„ุฉ ูˆุฌูˆุฏ ู‡ุฐู‡ ุงู„ุทูุฑุฉ T315I

Ad. Effect: hyperglycemia



#Leukemia

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ
โค6๐Ÿ˜1
https://docs.google.com/forms/d/e/1FAIpQLScA5T7dgGRnOW_yApZ1aCTo4MfYJAakxOjY6lsIzYfVF4XqtQ/viewform?usp=publish-editor

ุณู„ุงู… ุนู„ูŠูƒู… ุทู„ุงุจ
ู‡ุฐุง ุจุญุซ ุชุฎุฑุฌู†ุง
ุงู„ูŠ ู…ุตุงุจ ุจุฌุฑุซูˆู…ุฉ ุงู„ู…ุนุฏุฉ ุญุงู„ูŠุงู‹ ุงูˆ ุณุงุจู‚ุงู‹ ุงูˆ ูŠุนุฑู ุฃุญุฏ ู…ุตุงุจ ูŠุงุฑูŠุช ูŠู…ู„ูŠู‡
โค4